Home Journal of Army Medical University Article
PDF (1.1 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Abstract
Keywords
References
Show full outline
Hide outline
Publishing Language: Chinese

Bilirubin impairs the sorafenib sensitivity in Huh7 cells through fatty acid oxidation by up-regulating PPARα/CPT1A

Jun TAN, Chi ZHANG, Yan DONG, Houjie LIANG()
Department of Oncology, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China
Show Author Information

Abstract

Objective

To observe the effect of bilirubin (Bil) on sorafenib (Sor) in the treatment of liver cancer and explore the involved molecular mechanisms.

Methods

In vitro, Huh7 cells were treated with different concentration of Sor (0, 2, 4, 8, 16, 32 μmol/L), of Bil (0, 2.5, 5, 10, 20, 40 μmol/L) and of Sor (0, 2, 4, 8, 16, 32 μmol/L) +Bil (20 μmol/L) for 24, 48 and 72 h. Cell viability was detected by CCK-8 assay. Huh7 cells were treated with Sor (4 μmol/L), Bil (20 μmol/L) and Sor (4 μmol/L)+Bil (20 μmol/L), cell cycle was detected by flow cytometry after 48 h, and the effects of drugs on cell proliferation were detected by clone formation assay after 14 d. In vivo, 16 mice bearing xenografts of Huh7 cells were divided into Con group, Bil group (25 mg·kg-1·d-1), Sor group (15 mg·kg-1·d-1) and Bil (25 mg·kg-1·d-1) +Sor (15 mg·kg-1·d-1) group (n=4), according to the S type sampling method. The expression levels of peroxisome proliferator-activated receptor (PPARα) and carnitine palmityl transferase 1A (CPT1A) were detected by Western blotting and real time PCR. After etomoxir (Eto), the inhibitor of CPT1A, was added, CCK-8 and clone formation assay were used to verify the mechanisms correlated with PPARα/CPT1A.

Results

CCK-8 results showed that the inhibitory effect of Sor on Huh7 cells was in a dose and time-dependent manner (P<0.05), and Bil had no significant effect on Huh7 cells (P>0.05). Compared with Sor group, the cell proliferation in Bil+Sor group was increased (P<0.05), the relative cell colony formation rate was grown (P<0.05), and the number of cells in S phase was decreased (P<0.05). In vivo, results showed that the tumor volume and weight of Sor group were lower than that of Con group (P<0.05), and the tumor volume and weight of Bil+Sor group were higher than those of Sor group (P<0.05). Western blotting and RT-qPCR results showed that PPARα and CPT1A expression levels were increased in Bil+Sor group compared with Sor group (P<0.05). After Eto was added, the cell proliferation and the relative cell clone formation rate of Bil+Sor+Eto group were decreased compared with Bil+Sor group (P<0.05).

Conclusion

Bil impairs the antitumor effects of sorafenib treatment in hepatocellular carcinoma through fatty oxidation by up-regulating PPARα/CPT1A.

Keywords

hepatocellular carcinomasorafenibbilirubinfatty acid oxidationPPARα/CPT1A
CLC number: R735.7;R963;R979.1 Document code: A

References

[1]
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GlOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
Crossref Google Scholar
[2]
ZIOGAS I A, TSOULFAS G. Evolving role of sorafenib in the management of hepatocellular carcinoma[J]. World J Clin Oncol, 2017, 8(3): 203-213. DOI: 10.5306/wjco.v8.i3.203.
Crossref Google Scholar
[3]
HAMOUD A R, WEAVER L, STEC D E, et al. Bilirubin in the liver-gut signaling axis[J]. Trends Endocrinol Metab, 2018, 29(3): 140-150. DOI: 10.1016/j.tem.2018.01.002.
Crossref Google Scholar
[4]
STEC D E, JOHN K, TRABBIC C J, et al. Bilirubin binding to PPARα inhibits lipid accumulation[J]. PloS ONE, 2016, 11(4): e0153427. DOI: 10.1371/journal.pone.0153427.
Crossref Google Scholar
[5]
KUO Y H, WANG J H, HUNG C H, et al. Albumin-bilirubin grade predicts prognosis of HCC patients with sorafenib use[J]. J Gastroenterol Hepatol, 2017, 32(12): 1975-1981. DOI: 10.1111/jgh.13783.
Crossref Google Scholar
[6]
NGUYEN T T H, NGUYEN V H, NGUYEN V H, et al. Role of baseline albumin-bilirubin grade on predict overall survival among sorafenib-treated patients with hepatocellular carcinoma in Vietnam[J]. Cancer Control, 2019, 26(1): 1073274819865269. DOI: 10.1177/1073274819865269.
Crossref Google Scholar
[7]
TADA T, KUMADA T, TOYODA H, et al. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: an analysis using time-dependent receiver operating characteristic[J]. J Gastroenterol Hepatol, 2019, 34(6): 1066-1073. DOI: 10.1111/jgh.14564.
Crossref Google Scholar
[8]
FAUBERT B, SOLMONSON A, DEBERARDINIS R J. Metabolic reprogramming and cancer progression[J]. Science, 2020, 368(6487): eaaw5473. DOI: 10.1126/science.aaw5473.
Crossref Google Scholar
[9]
WANG Y G, XIA Y, LU Z M. Metabolic features of cancer cells[J]. Cancer Commun, 2018, 38(1): 65. DOI: 10.1186/s40880-018-0335-7.
Crossref Google Scholar
[10]
BENSINGER S J, CHRISTOFK H R. New aspects of the Warburg effect in cancer cell biology[J]. Semin Cell Dev Biol, 2012, 23(4): 352-361. DOI: 10.1016/j.semcdb.2012.02.003.
Crossref Google Scholar
[11]
KOPPENOL W H, BOUNDS P L, DANG C V. Otto Warburg’s contributions to current concepts of cancer metabolism[J]. Nat Rev Cancer, 2011, 11(5): 325-337. DOI: 10.1038/nrc3038.
Crossref Google Scholar
[12]
CAIRNS R A, HARRIS I S, MAK T W. Regulation of cancer cell metabolism[J]. Nat Rev Cancer, 2011, 11(2): 85-95. DOI: 10.1038/nrc2981.
Crossref Google Scholar
[13]
CHENG S T, WANG G, WANG Y, et al. Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer[J]. Clin Sci (lond), 2019, 133(15): 1745-1758. DOI: 10.1042/CS20190587.
Crossref Google Scholar
[14]
SENNI N, SAVALL M, CABRERIZO GRANADOS D, et al. Β-catenin-activated hepatocellular carcinomas are addicted to fatty acids[J]. Gut, 2019, 68(2): 322-334. DOI: 10.1136/gutjnl-2017-315448.
Crossref Google Scholar
[15]
RICCIARDI M R, MIRABILII S, ALLEGRETTI M, et al. Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias[J]. Blood, 2015, 126(16): 1925-1929. DOI: 10.1182/blood-2014-12-617498.
Crossref Google Scholar
[16]
MONTAGNER A, POLIZZI A, FOUCHÉ E, et al. liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFlD[J]. Gut, 2016, 65(7): 1202-1214. DOI: 10.1136/gutjnl-2015-310798.
Crossref Google Scholar
[17]
GORDON D M, BLOMQUIST T M, MIRUZZI S A, et al. RNA sequencing in human HepG2 hepatocytes reveals PPAR-α mediates transcriptome responsiveness of bilirubin[J]. Physiol Genomics, 2019, 51(6): 234-240. DOI: 10.1152/physiolgenomics.00028.2019.
Crossref Google Scholar
[18]
LOPASCHUK G D, WALL S R, OLLEY P M, et al. Etomoxir, a carnitine palmitoyltransferase Ⅰ inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine[J]. Circ Res, 1988, 63(6): 1036-1043. DOI: 10.1161/01.res.63.6.1036.
Crossref Google Scholar
Journal of Army Medical University
Volume 44 Issue 16,
August 2022
Pages 1606-1612
DOI: 10.16016/j.2097-0927.202201233
Cite this article:
TAN J, ZHANG C, DONG Y, et al. Bilirubin impairs the sorafenib sensitivity in Huh7 cells through fatty acid oxidation by up-regulating PPARα/CPT1A. Journal of Army Medical University, 2022, 44(16): 1606-1612. https://doi.org/10.16016/j.2097-0927.202201233
Metrics & Citations  
Article History
Copyright
Return